[
  {
    "drug_name": "ibuprofen",
    "brand_names": [
      "Motrin",
      "Advil",
      "Nurofen"
    ],
    "description": "Nonsteroidal anti-inflammatory drug (NSAID) used for analgesia, antipyresis and anti-inflammatory effects.",
    "primary_uses": [
      "Pain (mild-moderate)",
      "Fever",
      "Inflammatory conditions",
      "Patent ductus arteriosus (IV formulation in neonates)"
    ],
    "mechanism_of_action": "Non-selective reversible inhibition of cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.",
    "age_restrictions": {
      "min_age": 0,
      "max_age": null,
      "notes": "Oral OTC formulations generally recommended for children ≥6 months (check product labeling); IV neonatal use for PDA in preterm infants under specialist guidance."
    },
    "contraindications": [
      "Hypersensitivity to ibuprofen or other NSAIDs",
      "Active peptic ulcer disease",
      "Recent coronary artery bypass graft (CABG) surgery",
      "Third trimester of pregnancy"
    ],
    "cautions": [
      "History of gastrointestinal bleeding or peptic ulcer",
      "Renal impairment",
      "Cardiovascular disease or heart failure",
      "Concurrent anticoagulant use"
    ],
    "side_effects_common": [
      "Dyspepsia",
      "Nausea",
      "Headache",
      "Dizziness"
    ],
    "side_effects_serious": [
      "Gastrointestinal bleeding",
      "Acute kidney injury",
      "Cardiovascular thrombotic events (with long-term/high-dose use)",
      "Severe hypersensitivity including anaphylaxis"
    ],
    "condition_specific_side_effects": [
      {
        "condition": "Pregnancy",
        "effects": [
          "Premature closure of ductus arteriosus (especially 3rd trimester)"
        ]
      },
      {
        "condition": "Renal impairment",
        "effects": [
          "Worsening renal function, decreased renal perfusion"
        ]
      }
    ],
    "interactions": [
      {
        "drug": "Warfarin",
        "severity": "major",
        "reason": "Increased bleeding risk via additive anticoagulant effect and displacement of protein binding; NSAIDs impair platelet function."
      },
      {
        "drug": "ACE inhibitors (e.g., lisinopril)",
        "severity": "moderate",
        "reason": "Reduced antihypertensive effect and increased risk of renal impairment (NSAID + ACEi + diuretic = triple whammy)."
      }
    ],
    "pregnancy": {
      "category": "Avoid in 3rd trimester",
      "notes": "NSAIDs may be used cautiously earlier in pregnancy if necessary but are contraindicated in the third trimester due to risk of premature ductus arteriosus closure and fetal renal impairment."
    },
    "breastfeeding": {
      "safe": true,
      "notes": "Low levels in breastmilk; short-term use at therapeutic doses generally considered compatible with breastfeeding."
    },
    "dosage": {
      "adult": "200–400 mg orally every 4–6 hours as needed (OTC); maximum commonly 1200 mg/day OTC, up to 2400 mg/day under medical supervision for prescription regimens.",
      "child": "Dose by weight: commonly 5–10 mg/kg every 6–8 hours (check product labeling; infants and neonates require specialist dosing)."
    },
    "sources": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017463s105lbl.pdf",
      "https://www.ema.europa.eu/en/medicines/human/EPAR/ibuprofen-genorph",
      "https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ibuprofen-drug-facts-label"
    ]
  },
  {
    "drug_name": "amoxicillin",
    "brand_names": [
      "Amoxil",
      "Trimox",
      "Moxatag"
    ],
    "description": "A broad-spectrum beta-lactam (aminopenicillin) antibiotic used to treat a variety of bacterial infections.",
    "primary_uses": [
      "Otitis media",
      "Sinusitis",
      "Pharyngitis",
      "Community-acquired pneumonia",
      "Skin and soft tissue infections",
      "Helicobacter pylori (in combination)"
    ],
    "mechanism_of_action": "Bactericidal inhibition of bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.",
    "age_restrictions": {
      "min_age": 0,
      "max_age": null,
      "notes": "Oral suspensions available and commonly used in neonates/infants with weight-based dosing; follow specific product labeling."
    },
    "contraindications": [
      "History of severe hypersensitivity (anaphylaxis) to penicillins or beta-lactams"
    ],
    "cautions": [
      "Mononucleosis (high rate of rash)",
      "Renal impairment (dose adjustment may be required)"
    ],
    "side_effects_common": [
      "Diarrhoea",
      "Nausea",
      "Rash (non-allergic)"
    ],
    "side_effects_serious": [
      "Anaphylaxis",
      "Clostridioides difficile-associated diarrhoea",
      "Severe cutaneous adverse reactions (rare)"
    ],
    "condition_specific_side_effects": [
      {
        "condition": "Mononucleosis",
        "effects": [
          "High incidence of maculopapular rash when given amoxicillin"
        ]
      },
      {
        "condition": "Renal impairment",
        "effects": [
          "Accumulation and need for dose adjustment"
        ]
      }
    ],
    "interactions": [
      {
        "drug": "Allopurinol",
        "severity": "moderate",
        "reason": "Increased incidence of amoxicillin-related rash reported when co-administered (mechanism not fully defined)."
      },
      {
        "drug": "Methotrexate",
        "severity": "moderate",
        "reason": "Beta-lactams may reduce renal clearance of methotrexate, increasing toxicity risk."
      }
    ],
    "pregnancy": {
      "category": "Generally considered compatible (no controlled human studies showing fetal harm)",
      "notes": "Used in pregnancy when indicated; treat infections promptly."
    },
    "breastfeeding": {
      "safe": true,
      "notes": "Excreted in breastmilk in low amounts; considered compatible with breastfeeding."
    },
    "dosage": {
      "adult": "Typically 250–500 mg every 8 hours or 500–875 mg every 12 hours depending on indication.",
      "child": "Weight-based dosing commonly 25–45 mg/kg/day in divided doses for typical infections; up to 90 mg/kg/day for severe infections (use product labeling)."
    },
    "sources": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/50542s02950754s01950760s01950761s016lbl.pdf",
      "https://www.ema.europa.eu/en/medicines/human/referrals/amoxil",
      "https://www.ncbi.nlm.nih.gov/books/NBK548190/"
    ]
  },
  {
    "drug_name": "lisinopril",
    "brand_names": [
      "Zestril",
      "Prinivil"
    ],
    "description": "ACE inhibitor used to treat hypertension, heart failure, and to improve survival after myocardial infarction.",
    "primary_uses": [
      "Hypertension",
      "Heart failure",
      "Post-myocardial infarction",
      "Diabetic nephropathy (proteinuric kidney disease)"
    ],
    "mechanism_of_action": "Competitive inhibitor of angiotensin-converting enzyme (ACE), reducing conversion of angiotensin I to angiotensin II and decreasing aldosterone — causes vasodilation and reduced blood volume.",
    "age_restrictions": {
      "min_age": 0,
      "max_age": null,
      "notes": "Use in pediatric patients supported for certain indications and ages per product labeling; avoid in neonates with renal impairment without specialist advice."
    },
    "contraindications": [
      "History of angioedema related to previous ACE inhibitor therapy",
      "Pregnancy (should be discontinued when pregnancy detected)",
      "Bilateral renal artery stenosis (relative)"
    ],
    "cautions": [
      "Hyperkalaemia risk in renal impairment",
      "Use with potassium-sparing diuretics or potassium supplements",
      "Renal impairment — monitor function and electrolytes"
    ],
    "side_effects_common": [
      "Dry cough",
      "Dizziness",
      "Hyperkalaemia"
    ],
    "side_effects_serious": [
      "Angioedema (can be life-threatening)",
      "Acute renal failure (rare)"
    ],
    "condition_specific_side_effects": [
      {
        "condition": "Pregnancy",
        "effects": [
          "Fetal renal dysfunction, oligohydramnios, fetal skull hypoplasia, and death — discontinue ACE inhibitors when pregnancy is detected."
        ]
      },
      {
        "condition": "Renal artery stenosis",
        "effects": [
          "Markedly reduced renal function and risk of renal failure"
        ]
      }
    ],
    "interactions": [
      {
        "drug": "Potassium-sparing diuretics (e.g., spironolactone)",
        "severity": "major",
        "reason": "Additive hyperkalaemia risk."
      },
      {
        "drug": "NSAIDs (e.g., ibuprofen)",
        "severity": "moderate",
        "reason": "Reduced antihypertensive effect and increased risk of renal impairment when combined."
      }
    ],
    "pregnancy": {
      "category": "Contraindicated (fetal risk)",
      "notes": "ACE inhibitors are contraindicated in pregnancy due to fetal toxicity; discontinue as soon as pregnancy is detected."
    },
    "breastfeeding": {
      "safe": false,
      "notes": "Lisinopril is excreted in human milk; use caution and consider alternatives when breastfeeding."
    },
    "dosage": {
      "adult": "Initial 5–10 mg once daily, titrate up to 20–40 mg once daily depending on response.",
      "child": "Pediatric dosing is weight-based; refer to product labeling (some preparations approved for pediatric hypertension)."
    },
    "sources": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019777s064lbl.pdf",
      "https://www.ema.europa.eu/en/documents/referral/opinion-following-article-75-referral-lisinopril-biochemie-international-non-proprietary-name-inn-lisinopril-background-information-and-annexes_i_en.pdf",
      "https://www.ncbi.nlm.nih.gov/books/NBK538268/"
    ]
  },
  {
    "drug_name": "metformin",
    "brand_names": [
      "Glucophage",
      "Glumetza",
      "Riomet"
    ],
    "description": "Biguanide antihyperglycemic agent used as first-line therapy in type 2 diabetes mellitus.",
    "primary_uses": [
      "Type 2 diabetes mellitus",
      "Off-label: polycystic ovary syndrome (PCOS) adjunctive therapy"
    ],
    "mechanism_of_action": "Decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity; exact mechanism involves activation of AMP-activated protein kinase (AMPK) among others.",
    "age_restrictions": {
      "min_age": 10,
      "max_age": null,
      "notes": "Some formulations approved for pediatric use (≥10 years) for type 2 diabetes; check formulation labeling."
    },
    "contraindications": [
      "Severe renal impairment (eGFR <30 mL/min/1.73m2)",
      "Acute or chronic metabolic acidosis (including diabetic ketoacidosis)",
      "Hypersensitivity to metformin"
    ],
    "cautions": [
      "Use with caution in renal impairment (dose adjustment and monitoring)",
      "Risk of lactic acidosis in situations of hypoxia, sepsis, or dehydration",
      "Iodinated contrast procedures — consider withholding in patients with reduced renal function"
    ],
    "side_effects_common": [
      "Gastrointestinal upset (nausea, diarrhoea)",
      "Metallic taste",
      "Vitamin B12 deficiency with long-term use"
    ],
    "side_effects_serious": [
      "Lactic acidosis (rare but potentially fatal)"
    ],
    "condition_specific_side_effects": [
      {
        "condition": "Renal impairment",
        "effects": [
          "Increased risk of lactic acidosis; dose reduction or discontinuation may be required."
        ]
      },
      {
        "condition": "Vitamin B12 deficiency",
        "effects": [
          "Peripheral neuropathy risk with long-term therapy"
        ]
      }
    ],
    "interactions": [
      {
        "drug": "Cimetidine",
        "severity": "moderate",
        "reason": "May increase metformin plasma concentrations by reducing renal tubular secretion."
      },
      {
        "drug": "Iodinated contrast media",
        "severity": "major",
        "reason": "Risk of contrast-induced nephropathy leading to increased risk of lactic acidosis; consider withholding metformin."
      }
    ],
    "pregnancy": {
      "category": "Used in pregnancy when benefits outweigh risks (no clear teratogenic signal)",
      "notes": "Increasing use in pregnancy for gestational diabetes or PCOS; follow specialist guidance."
    },
    "breastfeeding": {
      "safe": true,
      "notes": "Metformin is excreted in breastmilk in small amounts; often considered compatible with breastfeeding."
    },
    "dosage": {
      "adult": "Initial 500 mg once or twice daily with meals, titrate to 2000 mg/day (commonly 500 mg twice daily to 1000 mg twice daily) depending on tolerance.",
      "child": "Pediatric dosing for type 2 diabetes: often 500 mg twice daily initial; refer to product labeling and specialist guidance."
    },
    "sources": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039%2C021202s021s023lbl.pdf",
      "https://www.ema.europa.eu/en/documents/scientific-guideline/metformin-immediate-release-film-coated-tablets-500-850-and-1000-mg-product-specific-bioequivalence-guidance_en.pdf"
    ]
  },
  {
    "drug_name": "albuterol",
    "brand_names": [
      "ProAir HFA",
      "Ventolin",
      "Salbutamol"
    ],
    "description": "Short-acting beta-2 adrenergic agonist (SABA) bronchodilator for relief of bronchospasm.",
    "primary_uses": [
      "Relief of acute bronchospasm in asthma and COPD",
      "Prevention of exercise-induced bronchospasm"
    ],
    "mechanism_of_action": "Selective agonist at beta-2 adrenergic receptors causing bronchial smooth muscle relaxation via increased cAMP.",
    "age_restrictions": {
      "min_age": 4,
      "max_age": null,
      "notes": "Some inhaler formulations approved for children ≥4 years; nebulized formulations may be used in younger children per product labeling."
    },
    "contraindications": [
      "Hypersensitivity to albuterol or formulation components"
    ],
    "cautions": [
      "Cardiovascular disease (arrhythmias, ischemia) — use with caution",
      "Diabetes (may cause hyperglycaemia)",
      "Hyperthyroidism"
    ],
    "side_effects_common": [
      "Tremor",
      "Palpitations",
      "Tachycardia",
      "Nervousness"
    ],
    "side_effects_serious": [
      "Paradoxical bronchospasm (may be life-threatening)",
      "Significant arrhythmias in susceptible individuals"
    ],
    "condition_specific_side_effects": [
      {
        "condition": "Cardiac disease",
        "effects": [
          "Exacerbation of tachyarrhythmias and myocardial ischemia due to beta-agonist effects."
        ]
      }
    ],
    "interactions": [
      {
        "drug": "Beta-blockers (non-selective)",
        "severity": "major",
        "reason": "Pharmacologic antagonism may reduce bronchodilatory effect and cause bronchospasm."
      },
      {
        "drug": "Diuretics (e.g., loop diuretics)",
        "severity": "moderate",
        "reason": "May potentiate hypokalaemia when used concomitantly with beta-2 agonists."
      }
    ],
    "pregnancy": {
      "category": "Use if clinically indicated (limited human data)",
      "notes": "Inhaled beta-2 agonists commonly used in pregnancy for asthma control; benefits typically outweigh risks."
    },
    "breastfeeding": {
      "safe": true,
      "notes": "Low systemic absorption from inhaled therapy; considered compatible with breastfeeding."
    },
    "dosage": {
      "adult": "Two inhalations (90–100 µg per actuation) every 4–6 hours as needed; for acute exacerbations follow inhaler/nebulizer dosing per product labeling.",
      "child": "Children ≥4 years: 2 inhalations every 4–6 hours as needed (refer to product labeling); nebulized solutions dosed by weight/clinic protocol."
    },
    "sources": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021457s036lbl.pdf",
      "https://www.medicines.org.uk/emc/product/850/smpc",
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021457s013lbl.pdf"
    ]
  },
  {
    "drug_name": "sertraline",
    "brand_names": [
      "Zoloft",
      "Lustral"
    ],
    "description": "Selective serotonin reuptake inhibitor (SSRI) antidepressant.",
    "primary_uses": [
      "Major depressive disorder",
      "Obsessive-compulsive disorder (OCD)",
      "Panic disorder",
      "PTSD",
      "Social anxiety disorder"
    ],
    "mechanism_of_action": "Selective inhibition of serotonin (5-HT) reuptake transporters (SERT), increasing synaptic serotonin levels.",
    "age_restrictions": {
      "min_age": 6,
      "max_age": null,
      "notes": "Approved for certain pediatric indications (e.g., OCD in children ≥6 years); monitor for suicidality in young people."
    },
    "contraindications": [
      "Concurrent use with MAO inhibitors or within 14 days of MAOI therapy",
      "Hypersensitivity to sertraline"
    ],
    "cautions": [
      "Increased risk of suicidal ideation in children/adolescents/young adults",
      "Serotonin syndrome risk with other serotonergic agents",
      "Use with anticoagulants or antiplatelet agents increases bleeding risk"
    ],
    "side_effects_common": [
      "Nausea",
      "Insomnia or somnolence",
      "Sexual dysfunction",
      "Diarrhoea"
    ],
    "side_effects_serious": [
      "Serotonin syndrome",
      "Increased suicidal ideation in young people",
      "Severe hyponatraemia (rare)"
    ],
    "condition_specific_side_effects": [
      {
        "condition": "Use with anticoagulants/antiplatelets",
        "effects": [
          "Increased bleeding risk due to impaired platelet aggregation when combined with SSRIs."
        ]
      }
    ],
    "interactions": [
      {
        "drug": "MAO inhibitors",
        "severity": "major",
        "reason": "Risk of life-threatening serotonin syndrome."
      },
      {
        "drug": "Warfarin",
        "severity": "moderate",
        "reason": "Increased INR and bleeding risk reported when SSRIs are co-administered with warfarin."
      }
    ],
    "pregnancy": {
      "category": "Use if clinically indicated (no consistent evidence of major teratogenicity)",
      "notes": "Consider risks of untreated depression vs potential neonatal adaptation syndrome; consult specialist."
    },
    "breastfeeding": {
      "safe": false,
      "notes": "Sertraline is present in breastmilk but often chosen among SSRIs when breastfeeding due to favorable infant exposure profile; monitor infant."
    },
    "dosage": {
      "adult": "50 mg once daily (range 25–200 mg/day depending on indication).",
      "child": "Pediatric dosing varies by indication (e.g., OCD: often 25 mg/day initial for children, titrate per weight/response) — follow product labeling."
    },
    "sources": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019839s74s86s87_20990s35s44s45lbl.pdf",
      "https://www.ema.europa.eu/en/documents/referral/zoloft-article-30-referral-annex-i-ii-iii-iv_en.pdf"
    ]
  },
  {
    "drug_name": "warfarin",
    "brand_names": [
      "Coumadin",
      "Jantoven"
    ],
    "description": "Vitamin K antagonist oral anticoagulant used for prevention and treatment of thromboembolic disorders.",
    "primary_uses": [
      "Prevention and treatment of venous thromboembolism (DVT/PE)",
      "Stroke prevention in atrial fibrillation (when indicated)",
      "Valve thrombosis prevention in mechanical heart valves"
    ],
    "mechanism_of_action": "Inhibits vitamin K epoxide reductase complex 1 (VKORC1), reducing gamma-carboxylation of vitamin K-dependent clotting factors II, VII, IX and X and anticoagulant proteins C and S.",
    "age_restrictions": {
      "min_age": 0,
      "max_age": null,
      "notes": "Neonatal use is complex; neonatal dosing/indications differ and require specialist management. Use in pediatrics only under specialist guidance."
    },
    "contraindications": [
      "Pregnancy when used for non-mechanical valve indications (teratogenic and bleeding risk)",
      "Uncontrolled bleeding",
      "Severe hepatic impairment with coagulopathy",
      "Hypersensitivity to warfarin"
    ],
    "cautions": [
      "Numerous drug–drug and drug–food interactions (vitamin K rich foods influence INR)",
      "Require frequent INR monitoring and dose adjustments",
      "Use caution in elderly and those with high bleeding risk"
    ],
    "side_effects_common": [
      "Bleeding (minor)",
      "Bruising"
    ],
    "side_effects_serious": [
      "Major bleeding (intracranial, gastrointestinal)",
      "Skin necrosis (rare)",
      "Teratogenicity when used in pregnancy (fetal warfarin syndrome)"
    ],
    "condition_specific_side_effects": [
      {
        "condition": "Pregnancy",
        "effects": [
          "Fetal warfarin syndrome (skeletal and nasal hypoplasia) and CNS abnormalities; avoid during pregnancy unless benefits outweigh risks (mechanical valves may warrant specialist management)."
        ]
      },
      {
        "condition": "Protein C or S deficiency",
        "effects": [
          "Transient hypercoagulable state on initiation; consider bridging with heparin"
        ]
      }
    ],
    "interactions": [
      {
        "drug": "NSAIDs (e.g., ibuprofen)",
        "severity": "major",
        "reason": "Increased bleeding risk due to additive antiplatelet effects and GI irritation."
      },
      {
        "drug": "Amoxicillin (oral broad-spectrum antibiotics)",
        "severity": "moderate",
        "reason": "Alteration of gut flora and vitamin K synthesis can affect INR; monitor closely."
      }
    ],
    "pregnancy": {
      "category": "Contraindicated for most of pregnancy (teratogenic)",
      "notes": "Warfarin is teratogenic and associated with fetal bleeding; specialist consultation required for anticoagulation in pregnancy."
    },
    "breastfeeding": {
      "safe": true,
      "notes": "Warfarin is poorly excreted in breastmilk and is considered compatible with breastfeeding when clinically indicated."
    },
    "dosage": {
      "adult": "Dose individualized to achieve target INR (commonly initial 5–10 mg/day for 1–2 days then adjust); maintenance varies (e.g., 2–10 mg/day).",
      "child": "Pediatric dosing individualized with frequent INR monitoring; specialist protocols apply."
    },
    "sources": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf",
      "https://www.medicines.org.uk/emc/product/14333/smpc",
      "https://www.ema.europa.eu/en/medicines/human/referrals/warfarin-sodium"
    ]
  },
  {
    "drug_name": "infliximab",
    "brand_names": [
      "Remicade",
      "Inflectra (biosimilar)"
    ],
    "description": "Chimeric monoclonal antibody (anti-TNF-alpha) biologic used to treat inflammatory autoimmune diseases.",
    "primary_uses": [
      "Rheumatoid arthritis",
      "Crohn's disease",
      "Ulcerative colitis",
      "Ankylosing spondylitis",
      "Psoriatic arthritis",
      "Plaque psoriasis"
    ],
    "mechanism_of_action": "Binds soluble and transmembrane tumor necrosis factor alpha (TNF-α), neutralizing its pro-inflammatory effects.",
    "age_restrictions": {
      "min_age": 6,
      "max_age": null,
      "notes": "Pediatric indications exist for certain conditions (e.g., Crohn's disease) from age 6 in some formulations; specialist management required."
    },
    "contraindications": [
      "Active severe infections (including sepsis, tuberculosis)",
      "Hypersensitivity to infliximab or murine proteins",
      "Moderate-to-severe heart failure (relative contraindication)"
    ],
    "cautions": [
      "Increased risk of serious infections including TB and opportunistic infections",
      "Risk of reactivation of hepatitis B",
      "Possible increased malignancy risk in some populations"
    ],
    "side_effects_common": [
      "Infusion reactions (fever, chills)",
      "Upper respiratory infections",
      "Headache"
    ],
    "side_effects_serious": [
      "Serious infections (including TB)",
      "Sepsis",
      "Rare demyelinating disorders",
      "Hepatosplenic T-cell lymphoma (very rare in young males on concomitant immunosuppressants)"
    ],
    "condition_specific_side_effects": [
      {
        "condition": "Latent tuberculosis",
        "effects": [
          "Reactivation of TB; mandatory screening before initiation."
        ]
      },
      {
        "condition": "Hepatitis B carrier state",
        "effects": [
          "Risk of reactivation; monitor viral markers and consider prophylaxis."
        ]
      }
    ],
    "interactions": [
      {
        "drug": "Live vaccines",
        "severity": "major",
        "reason": "Concomitant use with live vaccines contraindicated due to risk of disseminated infection in immunosuppressed patients."
      },
      {
        "drug": "Other biologic immunosuppressants (e.g., abatacept)",
        "severity": "major",
        "reason": "Increased risk of serious infections and immunosuppression; generally avoid combination therapy."
      }
    ],
    "pregnancy": {
      "category": "Use only if clearly needed (limited data)",
      "notes": "Limited human data; potential risks to fetus from immunosuppression — weigh maternal benefits and fetal risks; many clinicians time dosing around pregnancy and consult specialists."
    },
    "breastfeeding": {
      "safe": false,
      "notes": "Monoclonal antibodies are large proteins with minimal oral bioavailability; limited data—consult specialist; some guidelines consider breastfeeding acceptable but monitor infant."
    },
    "dosage": {
      "adult": "5 mg/kg IV at 0, 2 and 6 weeks, then every 8 weeks for many indications (dose and schedule vary by indication).",
      "child": "Pediatric dosing varies by indication and weight; e.g., Crohn's disease protocols often 5 mg/kg with similar induction schedule — specialist-guided."
    },
    "sources": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf",
      "https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf"
    ]
  },
  {
    "drug_name": "omeprazole",
    "brand_names": [
      "Prilosec",
      "Losec"
    ],
    "description": "Proton pump inhibitor (PPI) that suppresses gastric acid secretion.",
    "primary_uses": [
      "Gastroesophageal reflux disease (GERD)",
      "Peptic ulcer disease",
      "H. pylori eradication (component of combination therapy)",
      "Erosive esophagitis"
    ],
    "mechanism_of_action": "Irreversibly inhibits H+/K+ ATPase (proton pump) in gastric parietal cells, reducing gastric acid secretion.",
    "age_restrictions": {
      "min_age": 1,
      "max_age": null,
      "notes": "Some formulations approved for pediatric patients ≥1 year for GERD/erosive esophagitis; check product labeling for age-specific dosing."
    },
    "contraindications": [
      "Hypersensitivity to omeprazole or substituted benzimidazoles"
    ],
    "cautions": [
      "Long-term use associated with risk of bone fractures, hypomagnesaemia, B12 deficiency",
      "Masking of malignancy symptoms in persistent dyspepsia"
    ],
    "side_effects_common": [
      "Headache",
      "Nausea",
      "Abdominal pain",
      "Diarrhoea or constipation"
    ],
    "side_effects_serious": [
      "Clostridioides difficile infection (increased risk with PPI use)",
      "Hypomagnesaemia",
      "Acute interstitial nephritis (rare)"
    ],
    "condition_specific_side_effects": [
      {
        "condition": "Long-term therapy",
        "effects": [
          "Risk of osteoporosis-related fractures and B12 deficiency; monitor when appropriate."
        ]
      }
    ],
    "interactions": [
      {
        "drug": "Clopidogrel",
        "severity": "moderate",
        "reason": "Omeprazole may reduce activation of clopidogrel via CYP2C19 inhibition; consider alternative PPI if concerned."
      },
      {
        "drug": "Warfarin",
        "severity": "moderate",
        "reason": "Potential increase in INR; monitor anticoagulation when initiating or stopping omeprazole."
      }
    ],
    "pregnancy": {
      "category": "Use if clinically indicated (no proven teratogenicity)",
      "notes": "Short-term use in pregnancy for GERD is generally considered when benefits outweigh risks; consult specialist."
    },
    "breastfeeding": {
      "safe": true,
      "notes": "Present in breastmilk in small amounts; generally considered compatible with breastfeeding."
    },
    "dosage": {
      "adult": "20–40 mg once daily depending on indication.",
      "child": "Pediatric dosing depends on age/weight; some oral suspension/capsule formulations approved for children ≥1 year — follow product labeling."
    },
    "sources": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf",
      "https://www.ema.europa.eu/en/documents/referral/losec_en.pdf",
      "https://www.medicines.org.uk/emc/product/4895/smpc"
    ]
  },
  {
    "drug_name": "azithromycin",
    "brand_names": [
      "Zithromax",
      "Zmax"
    ],
    "description": "Macrolide antibiotic with broad activity against many respiratory and atypical pathogens.",
    "primary_uses": [
      "Community-acquired respiratory tract infections",
      "Atypical pneumonia (Mycoplasma, Chlamydia)",
      "Chlamydia trachomatis infections",
      "Some skin and soft tissue infections"
    ],
    "mechanism_of_action": "Binds to the 50S bacterial ribosomal subunit, inhibiting translocation and protein synthesis (bacteriostatic; may be bactericidal at high concentrations against some organisms).",
    "age_restrictions": {
      "min_age": 0,
      "max_age": null,
      "notes": "Oral suspension formulations available for infants/children; follow age/weight dosing in labeling. Recent EMA guidance has narrowed some indications to reduce resistance."
    },
    "contraindications": [
      "Known hypersensitivity to azithromycin or macrolide antibiotics",
      "History of cholestatic jaundice/hepatic dysfunction associated with azithromycin"
    ],
    "cautions": [
      "QT prolongation risk — use cautiously with other QT-prolonging drugs",
      "Severe hepatic impairment — monitor liver function"
    ],
    "side_effects_common": [
      "Diarrhoea",
      "Nausea",
      "Abdominal pain",
      "Vomiting"
    ],
    "side_effects_serious": [
      "QT prolongation and torsades de pointes (rare)",
      "Severe hepatic injury (rare)",
      "Allergic reactions including anaphylaxis (rare)"
    ],
    "condition_specific_side_effects": [
      {
        "condition": "Cardiac disease",
        "effects": [
          "Increased risk of arrhythmia and QT prolongation in patients with existing cardiac disease or on other QT-prolonging drugs."
        ]
      }
    ],
    "interactions": [
      {
        "drug": "Statins (e.g., simvastatin)",
        "severity": "moderate",
        "reason": "Increased risk of myopathy/rhabdomyolysis with certain statins; check specific statin interactions."
      },
      {
        "drug": "Antacids containing aluminum or magnesium",
        "severity": "minor",
        "reason": "May reduce oral azithromycin absorption if administered simultaneously; separate dosing intervals."
      }
    ],
    "pregnancy": {
      "category": "Generally considered compatible (no strong evidence of teratogenicity)",
      "notes": "Use when clinically indicated; consider alternatives based on infection and resistance patterns."
    },
    "breastfeeding": {
      "safe": true,
      "notes": "Azithromycin is excreted in breastmilk in low amounts; considered compatible with breastfeeding."
    },
    "dosage": {
      "adult": "Typical adult z‑pack: 500 mg on day 1 followed by 250 mg once daily on days 2–5; other regimens exist depending on formulation.",
      "child": "Weight-based dosing (e.g., 10 mg/kg day 1 then 5 mg/kg days 2–5) for many pediatric infections; follow product labeling."
    },
    "sources": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050670s036%2C050710s051%2C050711s050%2C050784s037lbl.pdf",
      "https://www.ema.europa.eu/en/medicines/human/referrals/azithromycin-containing-medicinal-products-systemic-use",
      "https://www.medicines.org.uk/emc/product/2272/smpc"
    ]
  }
]